Affomix has built and automated the tools to rapidly generate antibodies against native, as well as post-translationally modified, proteins. These specialized antibodies, which are designed to enable sensitive detection and accurate quantitation, are ideal for use in several existing platforms, including next generation sequencers, stated John Boyce, Head of Business Development for Affomix and Co-Founder of Delphi Bio, LLC. Collaborations with leading institutes such as City of Hope will enable us to expand our reach into the clinical diagnostics and personalized medicine markets. This is a transformative milestone in the merging of proteomics and genomics.

We are pleased to be working with an innovative partner such as City of Hope. The institution ™s ability to couple research programs with diagnostic test development is well documented. This collaboration will expand our efforts to extend the logical progression from nucleic acid-based to protein-based diagnostic analysis, stated Michael Sherman, President of Affomix.

SOURCE Affomix Corporation